About AlyoRA Capital Research
We are an independent equity research and investment advisory firm dedicated to bringing institutional-grade market clarity to retail and high-net-worth investors.
Built on Data. Driven by Integrity.
Research for Every Indian Investor
To democratise institutional financial research and make it accessible to every Indian investor — from the salaried professional running their first SIP to the HNI building a multi-crore equity portfolio.
- No investor left behind — scalable from ₹5,000 SIPs to crore-plus portfolios
- Institutional research quality at retail subscription price points
- Bridge the information asymmetry between retail and institutional market participants
SEBI-Aligned, Data-Driven Research
To deliver SEBI-aligned, data-driven financial research with complete transparency and zero broker bias — ensuring every subscriber receives an unfiltered, unbiased view of the markets.
- 100% subscription-funded — zero dependency on broker or corporate advisory fees
- SEBI Research Analyst framework compliance with full disclosure
- Transparent pricing with explicit deliverables for every plan tier
Founding Story & Core Principles
Founded in 2021, AlyoRA Capital Research was built to address a critical gap: unbiased, non-commission-driven financial analysis for retail and HNI investors. Unlike brokerage houses that profit from trading volume, our revenue comes solely from transparent subscriptions.
- Institutional-grade DCF & earnings models behind every recommendation
- Plain-language research — no jargon, no false complexity
- Conviction over coverage — we go deep, not wide
Why AlyoRA Stands Apart
Zero Broker Conflict
No hidden kickbacks or churn recommendations.
Institutional DCF Modeling
Every stock recommendation backed by a 5-year cashflow model.
SEBI Research Analyst Registered
Operating under SEBI's Research Analyst framework with full compliance.
Research Expertise at a Glance
Research you can trust. Advice you can act on.
Click any pillar to explore what sets AlyoRA apart from generic advisory firms.